CD8A and neoplasm: Type 1 cDCs (cDC1) are the major subset that can cross-present antigens and activate CD8 T cells through the major histocompatibility complex class I (MHC-I) pathway, and activate CD4 T cells through the MHC-II and CD4 signaling pathway to induce adaptive anti-tumor immune responses [112,115].